Challenges and opportunities for the next generation of cardiovascular tissue engineering
Open accessThe DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Abstract
Engineered cardiac tissues derived from human induced pluripotent stem cells offer unique opportunities for patient-specific disease modeling, drug discovery and cardiac repair. Since the first engineered hearts were introduced over two decades ago, human induced pluripotent stem cell-based three-dimensional cardiac organoids and heart-on-a-chip systems have now become mainstays in basic cardiovascular research as valuable platforms for investigating fundamental human pathophysiology and development. However, major obstacles remain to be addressed before the field can truly advance toward commercial and clinical translation. Here we provide a snapshot of the state-of-the-art methods in cardiac tissue engineering, with a focus on in vitro models of the human heart. Looking ahead, we discuss major challenges and opportunities in the field and suggest strategies for enabling broad acceptance of engineered cardiac tissues as models of cardiac pathophysiology and testbeds for the development of therapies. In this Perspective, technologies and challenges in the cardiac tissue engineering field are discussed and strategies to overcome these challenges are proposed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“current in vitro models for pharmaceutical screens are usually limited to one or very few cell types or lack the ability to mimic the blood‐flow generating pumping function of the heart through appropriate geometry and synchronous contraction.[ 13 , 14 ]”
From Engineered in vitro multi-cell type ventricle model generates long-term pulsatile flow and modulates cardiac output in response to cardioactive drugs (2025) · cites this paper as [13]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, models of cardiovascular disease lag behind other organ models,[ 9 ] often failing to mimic pulsatile flow and thus lacking a fundamental characteristic of human cardiac function.[ 13 , 14 ]”
From Engineered in vitro multi-cell type ventricle model generates long-term pulsatile flow and modulates cardiac output in response to cardioactive drugs (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Unfortunately, such models are unable to generate a pulsatile flow and therefore they lack the main function of the human heart.[ 13 , 14 ]”
From Engineered in vitro multi-cell type ventricle model generates long-term pulsatile flow and modulates cardiac output in response to cardioactive drugs (2025) · cites this paper as [13]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Langer, R., & Vacanti, J. P. (1993) · Science · doi:10.1126/science.8493529 · Cited by 9,893
Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart
Ott, H. C., Matthiesen, T. S., Goh, S.-K., Black, L. D., Kren, S. M., Netoff, T. I., & Taylor, D. A. (2008) · Nature Medicine · doi:10.1038/nm1684 · Cited by 2,650
Nuclear Lamin-A Scales with Tissue Stiffness and Enhances Matrix-Directed Differentiation
Swift, J., Ivanovska, I. L., Buxboim, A., Harada, T., Dingal, P. C. D. P., Pinter, J., Pajerowski, J. D., Spinler, K. R., Shin, J.-W., Tewari, M., et al. (2013) · Science · doi:10.1126/science.1240104 · Cited by 1,991
Self-citationRapid casting of patterned vascular networks for perfusable engineered three-dimensional tissues
Miller, J. S., Stevens, K. R., Yang, M. T., Baker, B. M., Nguyen, D.-H. T., Cohen, D. M., Toro, E., Chen, A. A., Galie, P. A., Yu, X., et al. (2012) · Nature Materials · doi:10.1038/nmat3357 · Cited by 1,917
Printing three-dimensional tissue analogues with decellularized extracellular matrix bioink
Pati, F., Jang, J., Ha, D.-H., Won Kim, S., Rhie, J.-W., Shim, J.-H., Kim, D.-H., & Cho, D.-W. (2014) · Nature Communications · doi:10.1038/ncomms4935 · Cited by 1,904
3D bioprinting of collagen to rebuild components of the human heart
Lee, A., Hudson, A. R., Shiwarski, D. J., Tashman, J. W., Hinton, T. J., Yerneni, S., Bliley, J. M., Campbell, P. G., & Feinberg, A. W. (2019) · Science · doi:10.1126/science.aav9051 · Cited by 1,782
Lian, X., Zhang, J., Azarin, S. M., Zhu, K., Hazeltine, L. B., Bao, X., Hsiao, C., Kamp, T. J., & Palecek, S. P. (2013) · Nature Protocols · doi:10.1038/nprot.2012.150 · Cited by 1,748
Chemically defined generation of human cardiomyocytes
Burridge, P. W., Matsa, E., Shukla, P., Lin, Z. C., Churko, J. M., Ebert, A. D., Lan, F., Diecke, S., Huber, B., Mordwinkin, N. M., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2999 · Cited by 1,606
Self-citationAdvanced maturation of human cardiac tissue grown from pluripotent stem cells
Ronaldson-Bouchard, K., Ma, S. P., Yeager, K., Chen, T., Song, L., Sirabella, D., Morikawa, K., Teles, D., Yazawa, M., & Vunjak-Novakovic, G. (2018) · Nature · doi:10.1038/s41586-018-0016-3 · Cited by 1,272
Self-citationHofer, M., & Lutolf, M. P. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00279-y · Cited by 1,184
Cited by
Zushin, P.-J. H., Mukherjee, S., & Wu, J. C. (2023) · Journal of Clinical Investigation · doi:10.1172/jci175824 · Cited by 347
“The incorporation of human-relevant in vitro models, such as human iPSCs (15), has gained traction as a robust substitute for animal testing in preclinical drug development.”
BackgroundSelf-citationMultimaterial 3D and 4D Bioprinting of Heterogenous Constructs for Tissue Engineering
Chen, A., Wang, W., Mao, Z., He, Y., Chen, S., Liu, G., Su, J. D., Feng, P., Shi, Y., Yan, C., et al. (2023) · Advanced Materials · doi:10.1002/adma.202307686 · Cited by 180
Khan, M. U. A., Aslam, M. A., Abdullah, M. F., Al-Arjan, W. S., Stojanović, G. M., & Hasan, A. (2024) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2024.105968 · Cited by 144
Collagen-based bioinks for regenerative medicine: Fabrication, application and prospective
Li, Z., Ruan, C., & Niu, X. (2023) · Medicine in Novel Technology and Devices · doi:10.1016/j.medntd.2023.100211 · Cited by 72
Application of new approach methodologies for nonclinical safety assessment of drug candidates
Beilmann, M., Adkins, K., Boonen, H. C. M., Hewitt, P. G., Hu, W., Mader, R., Moore, S., Rana, P., Steger‐Hartmann, T., Villenave, R., et al. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01182-9 · Cited by 85
Metadata
- Authors
- Cho, S., Discher, D. E., Leong, K. W., Vunjak-Novakovic, G., & Wu, J. C.
- Affiliations
- Stanford Medicine (US)
- University of Pennsylvania (US)
- Columbia University (US)
- Corresponding author
- Wu, Joseph C.
- Venue
- Nature Methods
- Published
- 2022-09
- Volume
- 19
- Issue
- 9
- Pages
- 1064-1071
- ISSN
- 1548-7091 (ISSN-L)
- 1548-7105
- PMC
- PMC12061062
- OpenAlex
- W4294636458
- Semantic Scholar
- 7e3dd70009ed619040213c7eb59d947169925ad2
- Cited by
- 176
- References
- 86
- Citations by year
- 2026: 37 · 2025: 50 · 2024: 53 · 2023: 32 · 2022: 4
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Methods (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Health & Human Services | National Institutes of Health (R01 HL126527, R01 HL130020, R01 HL146690, R01 HL150693, UH3 TR002588, F32 HL152483)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Keywords
- cardiovascular tissue engineering, human induced pluripotent stem cells, cardiac organoids, heart-on-a-chip, engineered heart tissue, patient-specific disease modeling, cardiac repair, drug discovery, clinical translation, cardiac pathophysiology
- MeSH terms
- Heart, Humans, Organoids, Tissue Engineering, Myocytes, Cardiac, Drug Discovery, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Challenges and opportunities for the next generation of cardiovascular tissue engineering. https://app.cochat.ai/papers/10.1038/s41592-022-01591-3
- The paper
- Cho, S., Discher, D. E., Leong, K. W., Vunjak-Novakovic, G., & Wu, J. C. (2022). Challenges and opportunities for the next generation of cardiovascular tissue engineering. Nature Methods. https://doi.org/10.1038/s41592-022-01591-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.